COMBINATIONS OF HEPARIN COFACTOR II AGONIST AND PLATELET IIB/IIIA ANTAGONIST, AND USES THEREOF

摘要

Combined use of a heparin cofactor II agonist and a platelet GPIIb/IIIareceptor antagonist to inhibit both platelet aggregation and thrombingeneration resulting from disease, injury or responses to wound repairs. Thecombined use of the heparin cofactor II agonist and the platelet GPIIb/IIIareceptor antagonist can achieve these therapeutic benefits while at the sametime minimizing or reducing the risk of hemorrhagic side effects (e.g.,prolonged bleeding), and without causing undesired antigenic responses.Moreover, certain subtherapeutic amounts of a platelet GPIIb/IIIa receptorantagonist can, in combination, be therapeutically effective in inhibitingboth platelet aggregation and thrombin generation.